Last reviewed · How we verify
Twymeeg (IMEGLIMIN)
Twymeeg (generic name: IMEGLIMIN) is a Small molecule drug developed by SUMITOMO DAINIPPON PHARMA Co., Ltd.. It is currently FDA-approved for Diabetes mellitus type 2.
At a glance
| Generic name | IMEGLIMIN |
|---|---|
| Sponsor | SUMITOMO DAINIPPON PHARMA Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetes mellitus type 2
Common side effects
Key clinical trials
- Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy (PHASE4)
- Bioequivalence Assessment Between Two Imeglimin Hydrochloride Film Coated Tablet Formulations (PHASE1)
- Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects (PHASE1)
- Bioequivalence of Imeglimin Tablet Formulations (PHASE1)
- Effect of Cimetidine on the PK of Imeglimin (PHASE1)
- Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects (PHASE1)
- Safety, Tolerability and PK of Imeglimin in Japanese Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Twymeeg CI brief — competitive landscape report
- Twymeeg updates RSS · CI watch RSS
- SUMITOMO DAINIPPON PHARMA Co., Ltd. portfolio CI
Frequently asked questions about Twymeeg
What is Twymeeg?
Twymeeg (IMEGLIMIN) is a Small molecule drug developed by SUMITOMO DAINIPPON PHARMA Co., Ltd., indicated for Diabetes mellitus type 2.
What is Twymeeg used for?
Twymeeg is indicated for Diabetes mellitus type 2.
Who makes Twymeeg?
Twymeeg is developed and marketed by SUMITOMO DAINIPPON PHARMA Co., Ltd. (see full SUMITOMO DAINIPPON PHARMA Co., Ltd. pipeline at /company/sumitomo-dainippon-pharma-co-ltd).
What is the generic name of Twymeeg?
IMEGLIMIN is the generic (nonproprietary) name of Twymeeg.
What development phase is Twymeeg in?
Twymeeg is FDA-approved (marketed).
Related
- Manufacturer: SUMITOMO DAINIPPON PHARMA Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Diabetes mellitus type 2
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing